Q. T. Ostrom, H. Gittleman, and J. Xu, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013, Neuro-Oncol, vol.18, pp.1-75, 2016.

J. P. Thakkar, T. A. Dolecek, and C. Horbinski, Epidemiologic and Molecular Prognostic Review of Glioblastoma, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, vol.23, pp.1985-1996, 2014.

S. Zouaoui, V. Rigau, and H. Mathieu-daudé, , 2012.

, Neurochirurgie, vol.58, pp.4-13

I. Baldi, A. Huchet, L. Bauchet, and H. Loiseau, , 2010.

, Neurochirurgie, vol.56, pp.433-440

L. Bauchet, H. Mathieu-daudé, and P. Fabbro-peray, Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004, Neuro-Oncol, vol.12, pp.725-735, 2010.

N. R. Smoll, K. Schaller, and O. P. Gautschi, Long-term survival of patients with glioblastoma multiforme (GBM), J Clin Neurosci Off J Neurosurg Soc Australas, vol.20, pp.670-675, 2013.

D. R. Johnson, D. J. Ma, J. C. Buckner, and J. E. Hammack, Conditional probability of longterm survival in glioblastoma: a population-based analysis, Cancer, vol.118, pp.5608-5613, 2012.

J. Li, M. Wang, and M. Won, Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma, Int J Radiat Oncol, vol.81, pp.623-630, 2011.

H. Yan, D. W. Parsons, and G. Jin, IDH1 and IDH2 mutations in gliomas, N Engl J Med, vol.360, pp.765-773, 2009.

D. W. Parsons, S. Jones, and X. Zhang, An integrated genomic analysis of human glioblastoma multiforme, Science, vol.321, pp.1807-1812, 2008.

M. E. Hegi, A. Diserens, and T. Gorlia, Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3, N Engl J Med, vol.352, pp.29-38, 2005.

R. Verhaak, K. A. Hoadley, and E. Purdom, An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1, Cancer Cell, vol.17, pp.1061-1068, 2006.

C. W. Brennan, R. Verhaak, and A. Mckenna, The Somatic Genomic Landscape of Glioblastoma, Cell, vol.155, pp.462-477, 2013.

R. Stupp, W. P. Mason, and M. J. Van-den-bent, Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, N Engl J Med, vol.352, pp.987-996, 2005.

R. Stupp, M. E. Hegi, and W. P. Mason, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, pp.459-466, 2009.

M. Weller, M. Van-den-bent, and K. Hopkins, EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma, Lancet Oncol, vol.15, pp.395-403, 2014.

R. Stupp, S. Taillibert, and A. Kanner, Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial, JAMA, vol.318, pp.2306-2316, 2017.

P. Y. Wen, D. R. Macdonald, and D. A. Reardon, New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials, Eur J Cancer Oxf Engl, vol.28, pp.1176-1184, 1990.

K. Seystahl, W. Wick, and M. Weller, Therapeutic options in recurrent glioblastoma--An update, Crit Rev Oncol Hematol, vol.99, pp.1182-1186, 1971.

J. Folkman, Opinion: Angiogenesis: an organizing principle for drug discovery?, Nat Rev Drug Discov, vol.6, pp.273-286, 2007.

N. J. Abbott, L. Rönnbäck, and E. Hansson, Astrocyte-endothelial interactions at the blood-brain barrier, Nat Rev Neurosci, vol.7, pp.41-53, 2006.

R. K. Jain, E. Di-tomaso, and D. G. Duda, Angiogenesis in brain tumours, Nat Rev Neurosci, vol.8, pp.610-622, 2007.

P. Kleihues and H. Ohgaki, Phenotype vs genotype in the evolution of astrocytic brain tumors, Toxicol Pathol, vol.28, pp.164-170, 2000.

T. P. Padera, B. R. Stoll, and J. B. Tooredman, Pathology: cancer cells compress intratumour vessels, Nature, vol.427, p.695, 2004.

N. Ferrara, K. J. Hillan, H. Gerber, and W. Novotny, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat Rev Drug Discov, vol.3, pp.391-400, 2004.

P. Carmeliet, R. Jain, C. Lu-emerson, D. G. Duda, and K. E. Emblem, Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.473, pp.1197-1213, 2011.

J. Holash, P. C. Maisonpierre, and D. Compton, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science, vol.284, pp.1994-1998, 1999.

R. Du, K. V. Lu, and C. Petritsch, HIF1? Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion, Cancer Cell, vol.13, pp.206-220, 2008.

D. Hambardzumyan and G. Bergers, Glioblastoma: Defining Tumor Niches, Trends Cancer, vol.1, pp.252-265, 2015.

A. Das, R. R. Cheng, and M. Hilbert, Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma, Cancer Growth Metastasis, vol.8, pp.51-60, 2015.

J. Chen, Y. Li, and T. Yu, A restricted cell population propagates glioblastoma growth following chemotherapy, Nature, vol.488, pp.522-526, 2012.

L. Cheng, Z. Huang, and W. Zhou, Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth, Cell, vol.153, pp.139-152, 2013.

R. Wang, K. Chadalavada, and J. Wilshire, Glioblastoma stem-like cells give rise to tumour endothelium, Nature, vol.468, pp.829-833, 2010.

P. Ø. Sakariassen, L. Prestegarden, and J. Wang, Angiogenesis-independent tumor growth mediated by stem-like cancer cells, Proc Natl Acad Sci U S A, vol.103, pp.16466-16471, 2006.

W. Leenders, B. Küsters, and R. De-waal, Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis, Endothel J Endothel Cell Res, vol.9, pp.83-87, 2002.

R. K. Jain, ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA, Cancer Cell, vol.26, pp.605-622, 2014.
DOI : 10.1016/j.ccell.2014.10.006

URL : https://doi.org/10.1016/j.ccell.2014.10.006

B. Qian, J. W. Pollard, R. Noy, J. W. Pollard, M. Z. Noman et al., PD-L1 is a novel direct target of HIF-1?, and its blockade under hypoxia enhanced MDSC-mediated T cell activation, J Exp Med, vol.141, pp.781-790, 2010.

Z. Li, S. Bao, and Q. Wu, Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells, Cancer Cell, vol.15, pp.501-513, 2009.

S. Watkins, S. Robel, and I. F. Kimbrough, Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells, Nat Commun, vol.5, p.4196, 2014.

F. Yuan, Y. Chen, and M. Dellian, Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody, Proc Natl Acad Sci, pp.14765-14770, 1996.

K. El-alaoui-lasmaili, E. Djermoune, and J. Tylcz, A new algorithm for a better characterization and timing of the anti-VEGF vascular effect named "normalization, Angiogenesis, vol.20, pp.149-162, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01416154

L. Von-baumgarten, D. Brucker, and A. Tirniceru, Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, pp.6192-6205, 2011.

O. Keunen, M. Johansson, and A. Oudin, Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma, Proc Natl Acad Sci U S A, vol.108, pp.3749-3754, 2011.
DOI : 10.1073/pnas.1014480108

URL : http://www.pnas.org/content/108/9/3749.full.pdf

H. Hurwitz, L. Fehrenbacher, and W. Novotny, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, vol.350, pp.2335-2342, 2004.
DOI : 10.1056/nejmoa032691

O. L. Chinot, W. Wick, and W. Mason, Bevacizumab plus RadiotherapyTemozolomide for Newly Diagnosed Glioblastoma, N Engl J Med, vol.370, pp.709-722, 2014.
DOI : 10.1056/nejmoa1308345

URL : http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf

M. R. Gilbert, J. J. Dignam, and T. S. Armstrong, A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma, N Engl J Med, vol.370, pp.699-708, 2014.

E. T. Wong, S. Gautam, and C. Malchow, Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis, J Natl Compr Cancer Netw JNCCN, vol.9, pp.403-407, 2011.
DOI : 10.6004/jnccn.2011.0037

W. Wick, T. Gorlia, and M. Bendszus, Lomustine and Bevacizumab in Progressive Glioblastoma, N Engl J Med, vol.377, pp.1954-1963, 2017.
DOI : 10.1056/nejmoa1707358

G. Lombardi, A. Pambuku, and L. Bellu, Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials, Crit Rev Oncol Hematol, vol.111, pp.94-102, 2017.

M. Khasraw, M. S. Ameratunga, and R. Grant, Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma, Cochrane Database of Systematic Reviews, vol.59, pp.4733-4740, 2009.

T. N. Kreisl, L. Kim, and K. Moore, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, pp.740-745, 2009.

E. P. Sulman, M. Won, and D. T. Blumenthal, Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma, 2013.

, J Clin Oncol, vol.31, pp.2010-2010

T. Sandmann, R. Bourgon, and J. Garcia, Erdem-Eraslan L, Bent MJ van den, Hoogstrate Y, et al (2016) Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, pp.525-534, 2015.

J. Laffaire, A. Stefano, and O. Chinot, An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas, BioMed Res Int, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01308273

E. Tabouret, F. Boudouresque, and M. Barrie, Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma, Neuro-Oncol, vol.16, pp.392-399, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01707899

C. Schaub, J. Tichy, and N. Schäfer, Prognostic factors in recurrent glioblastoma patients treated with bevacizumab, J Neurooncol, vol.129, pp.93-100, 2016.

N. K. Gerber, A. Goenka, and S. Turcan, Transcriptional diversity of long-term glioblastoma survivors, Neuro-Oncol, vol.16, pp.1186-1195, 2014.

W. L. Bi and R. Beroukhim, Beating the odds: extreme long-term survival with glioblastoma, Neuro-Oncol, vol.16, pp.1159-1160, 2014.

L. Gately, S. Mclachlan, and J. Philip, Long-term survivors of glioblastoma: a closer look, J Neurooncol, vol.136, pp.155-162, 2018.

D. R. Johnson, A. Omuro, and A. Ravelo, Overall survival in patients with glioblastoma before and after bevacizumab approval, Curr Med Res Opin, vol.34, pp.813-820, 2018.

D. R. Johnson, H. E. Leeper, and J. H. Uhm, Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis, Cancer, vol.119, pp.3489-3495, 2013.

A. M. Henaine, N. Paubel, and F. Ducray, Current trends in the management of glioblastoma in a French University Hospital and associated direct costs, J Clin Pharm Ther, vol.41, pp.47-53, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01804493

C. Chen, A. Ravelo, and E. Yu, Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices, J Neurooncol, vol.122, pp.595-605, 2015.

D. Gramatzki, P. Roth, and E. J. Rushing, Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study, Ann Oncol Off J Eur Soc Med Oncol, 2018.

M. D. Anderson, M. A. Hamza, K. R. Hess, and V. K. Puduvalli, Implications of bevacizumab discontinuation in adults with recurrent glioblastoma, Neuro-Oncol, vol.16, pp.823-828, 2014.

C. Bronnimann, C. Izquierdo, and S. Cartalat, Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy, J Neurooncol, 2018.

A. Hertenstein, T. Hielscher, and O. Menn, Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma, J Neurooncol, vol.129, pp.533-539, 2016.

E. Franceschi, G. Lamberti, and A. Paccapelo, Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?, Future Oncol Lond Engl, vol.10, pp.1137-1145, 2014.

D. A. Reardon, J. E. Herndon, and K. B. Peters, Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients, Br J Cancer, vol.107, pp.1481-1487, 2012.

M. A. Hamza, J. J. Mandel, and C. A. Conrad, Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma, J Neurooncol, vol.119, pp.815-822, 2014.

B. Wiestler, A. Radbruch, and M. Osswald, Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma, J Neurooncol, vol.117, pp.85-92, 2014.

M. Polley, K. R. Lamborn, and S. M. Chang, Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide, Neuro-Oncol, vol.12, pp.274-282, 2010.

L. S. Rowe, J. A. Butman, and M. Mackey, Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM, J Neurooncol, 2018.

W. Taal, D. Brandsma, and H. G. De-bruin, Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide, Cancer, vol.113, pp.405-410, 2008.

W. Wick, O. L. Chinot, and M. Bendszus, Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma, Neuro-Oncol, vol.18, pp.1434-1441, 2016.

B. M. Ellingson, C. Chung, and W. B. Pope, Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape, J Neurooncol, vol.134, pp.495-504, 2017.

V. A. Levin, L. Bidaut, and P. Hou, Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis, Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex, vol.79, pp.1487-1495, 2011.

J. Duerinck, P. M. Clement, and F. Bouttens, Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma, J Neurol, vol.262, pp.742-751, 2015.

E. T. Wong, E. Lok, S. Gautam, and K. D. Swanson, Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma, Br J Cancer, vol.113, p.1642, 2015.

K. L. Pitter, I. Tamagno, and K. Alikhanyan, Corticosteroids compromise survival in glioblastoma, Brain J Neurol, vol.139, pp.1458-1471, 2016.

G. Minniti, L. Agolli, and T. Falco, Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas, J Neurooncol, vol.122, pp.559-566, 2015.

M. Flieger, U. Ganswindt, and S. B. Schwarz, Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option, J Neurooncol, vol.117, pp.337-345, 2014.

A. A. Brandes, M. Bartolotti, and A. Tosoni, Practical management of bevacizumab-related toxicities in glioblastoma, The Oncologist, vol.20, pp.166-175, 2015.

X. Li, R. Huang, and Z. Xu, Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta, Analysis. Sci Rep, vol.5, p.14698, 2015.

J. J. Vredenburgh, T. Cloughesy, and M. Samant, Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study, The Oncologist, vol.15, pp.1329-1334, 2010.

C. Chen, R. Huang, and A. Maclean, Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival, J Neurooncol, vol.115, pp.267-276, 2013.

S. Lv, E. Teugels, and J. Sadones, Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma, Anticancer Res, vol.31, pp.4457-4463, 2011.

A. Amelot, P. De-cremoux, and V. Quillien, IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients, PloS One, vol.10, p.130596, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01305489

C. Hartmann, B. Hentschel, and M. Simon, Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations, Clin Cancer Res, vol.19, pp.5146-5157, 2013.

K. Han, M. Ren, and W. Wick, Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials, NeuroOncol, vol.16, pp.696-706, 2014.

M. Taphoorn, R. Henriksson, and A. Bottomley, Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma, J Clin Oncol, vol.33, pp.2166-2175, 2015.

L. Dirven, M. J. Van-den-bent, and A. Bottomley, The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial, Eur J Cancer Oxf Engl, vol.51, pp.1321-1330, 1990.

V. A. Levin, J. Chan, and M. Datta, Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab, J Neurooncol, vol.134, pp.325-330, 2017.

V. Lorgis, G. Maura, and G. Coppa, Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts, J Neurooncol, vol.107, pp.351-358, 2012.
DOI : 10.1007/s11060-011-0748-5

A. Ajlan, P. Thomas, and A. Albakr, Optimizing bevacizumab dosing in glioblastoma: less is more, J Neurooncol, vol.135, pp.99-105, 2017.
DOI : 10.1007/s11060-017-2553-2

J. F. De-groot, High-dose antiangiogenic therapy for glioblastoma: less may be more?, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, pp.6109-6111, 2011.

T. T. Batchelor, E. R. Gerstner, and K. E. Emblem, Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation, Proc Natl Acad Sci U S A, vol.110, pp.19059-19064, 2013.
DOI : 10.1073/pnas.1318022110

URL : http://www.pnas.org/content/110/47/19059.full.pdf

A. G. Sorensen, T. T. Batchelor, and W. Zhang, A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients, Cancer Res, vol.69, pp.5296-5300, 2009.

A. G. Sorensen, K. E. Emblem, and P. Polaskova, Increased Survival of Glioblastoma Patients who Respond to Anti-angiogenic Therapy with Elevated Blood Perfusion, Cancer Res, vol.72, pp.402-407, 2012.

K. E. Emblem, K. Mouridsen, and A. Bjornerud, Vessel Architectural Imaging Identifies Cancer Patient Responders to Anti-angiogenic Therapy, Nat Med, vol.19, pp.1178-1183, 2013.
DOI : 10.1038/nm.3289

URL : http://europepmc.org/articles/pmc3769525?pdf=render

D. Hambardzumyan, D. H. Gutmann, and H. Kettenmann, The role of microglia and macrophages in glioma maintenance and progression, Nat Neurosci, vol.19, pp.20-27, 2016.

D. F. Quail and J. A. Joyce, The Microenvironmental Landscape of Brain Tumors, Cancer Cell, vol.31, pp.326-341, 2017.